公开(公告)号：AU2002360489A1

公开(公告)日：2003-06-23

申请号：AU2002360489

申请日：2002-12-06

Applicant: BAILEY KATHY ,  KANE JOHN ,  ISHIDA BRIAN ,  SCHWARTZ DANIEL M ,  DUNCAN KEITH

Inventor： BAILEY KATHY ,  KANE JOHN ,  ISHIDA BRIAN ,  SCHWARTZ DANIEL M ,  DUNCAN KEITH

IPC: A61K45/00 ,  A61K31/00 ,  A61K31/192 ,  A61K31/198 ,  A61K31/203 ,  A61K31/381 ,  A61K31/44 ,  A61K31/56 ,  A61K31/575 ,  A61K31/58 ,  A61P27/02

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

公开(公告)号：WO2005091909A3

公开(公告)日：2007-11-22

申请号：PCT/US2005006554

申请日：2005-03-01

Applicant: UNIV CALIFORNIA ,  SCHWARTZ DANIEL M ,  DUNCAN KEITH G ,  BAILEY KATHY R ,  KANE JOHN ,  ISHIDA BRIAN Y

Inventor： SCHWARTZ DANIEL M ,  DUNCAN KEITH G ,  BAILEY KATHY R ,  KANE JOHN ,  ISHIDA BRIAN Y

IPC: A61K31/685 ,  A61K31/56 ,  A61K31/66 ,  A61K38/10 ,  A61K38/17

CPC classification number: A61K31/685 ,  A61K31/66 ,  A61K38/17 ,  A61K38/1709 ,  A61K2300/00

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

Abstract translation: 本发明通过调节与动脉粥样硬化相似的致病机制来解决年龄相关性黄斑变性的治疗。 在另外的具体实施方案中，增加反向胆固醇转运的组合物被用作年龄相关性黄斑变性的治疗靶标。 在一个具体的实施方案中，通过递送载脂蛋白A1，特别是模拟肽来减少视网膜色素上皮和/或Bruch's膜的脂质含量。

公开(公告)号：WO2006039551A3

公开(公告)日：2006-04-13

申请号：PCT/US2005/035294

申请日：2005-09-30

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE CALIFORNIA INSTITUTE OF TECHNOLOGY ,  DAVIS, Mark E. ,  SCHWARTZ, Daniel M.

Inventor： DAVIS, Mark E. ,  SCHWARTZ, Daniel M.

IPC: A61K31/07

Abstract: The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.

公开(公告)号：WO2005110397A1

公开(公告)日：2005-11-24

申请号：PCT/US2005/016072

申请日：2005-05-09

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE CALIFORNIA INSTITUTE OF TECHNOLOGY ,  SCHWARTZ, Daniel, M. ,  YU, Chang, Jun ,  GRUBBS, Robert, H. ,  KORNFIELD, Julia, A. ,  FRASER, Scott, E. ,  MATTSON, Matthew, S.

Inventor： SCHWARTZ, Daniel, M. ,  YU, Chang, Jun ,  GRUBBS, Robert, H. ,  KORNFIELD, Julia, A. ,  FRASER, Scott, E. ,  MATTSON, Matthew, S.

IPC: A61K31/295

CPC classification number: A61K31/135 ,  A61K31/295 ,  A61K31/325 ,  A61K31/37 ,  A61K31/382 ,  A61K31/47 ,  A61K31/495 ,  A61K41/0042 ,  A61K49/0002

Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.

Abstract translation: 本发明涉及改变眼睛中至少一个组织的至少一部分的物理和/或化学性质。 在具体实施方案中，其涉及治疗和/或预防近视。 活化能源用于光聚合或交联巩膜中的分子，从而增加组织的强度。 给个体施用交联剂或可光聚合的分子，其与膜相关联，然后将其精确地暴露于能量源，例如光或超声波。

公开(公告)号：WO2005107649A2

公开(公告)日：2005-11-17

申请号：PCT/US2005/014939

申请日：2005-04-29

Applicant: CALHOUN VISION, INC. ,  GRUBBS, Robert, H. ,  BRAIT, Axel ,  CHANG, Shiao, H. ,  NISHI, Okihiro ,  SCHWARTZ, Daniel, M.

Inventor： GRUBBS, Robert, H. ,  BRAIT, Axel ,  CHANG, Shiao, H. ,  NISHI, Okihiro ,  SCHWARTZ, Daniel, M.

IPC: A61F2/16

CPC classification number: A61F2/1613 ,  A61F2/1629 ,  A61F2/1635 ,  A61F9/0017 ,  A61F2002/30583 ,  A61F2210/0085 ,  A61F2250/0012 ,  A61L31/06 ,  A61L2430/16 ,  C08L83/04

Abstract: The invention relates to a novel composition for improving the accommodation capability of an intraocular lens (IOL). In one embodiment, the composition can be injected into the capsular bag where it surrounds an implanted IOL anchoring the IOL to the capsular bag. Alternatively, for anterior chamber IOLs, the composition can be injected into the bag behind the lens. The material has a refractive index similar to that of aqueous thereby reducing any potential interference with the implanted IOL. Accommodation is provided by the mixture of the crosslinked composition caused by the flexing of the muscles. The novel composition is particularly useful in enhancing accommodation for adjustable intraocular lenses.

Abstract translation: 本发明涉及一种用于改善人工晶状体（IOL）适应能力的新型组合物。 在一个实施方案中，组合物可以注射到囊袋中，其中其围绕将IOL锚定到囊袋的植入的IOL。 或者，对于前房IOL，可以将组合物注入镜片后面的袋中。 该材料具有类似于水的折射率，从而减少与植入的IOL的任何潜在干扰。 通过由肌肉的弯曲引起的交联组合物的混合物提供住宿。 该新颖的组合物特别可用于增加可调节眼内透镜的适应性。

公开(公告)号：WO2005072223A3

公开(公告)日：2005-09-09

申请号：PCT/US2005001773

申请日：2005-01-21

Applicant: CALIFORNIA INST OF TECHN ,  UNIV CALIFORNIA SAN FRANCISCO ,  TIRRELL DAVID A ,  SCHWARTZ DANIEL M ,  NOWATZKI PAUL J ,  GRUBBS ROBERT H

Inventor： TIRRELL DAVID A ,  SCHWARTZ DANIEL M ,  NOWATZKI PAUL J ,  GRUBBS ROBERT H

IPC: A61F2/14 ,  A61F2/16 ,  A61K9/00 ,  A61L27/22 ,  A61L27/34 ,  C07K14/78 ,  C12N15/00

CPC classification number: C07K14/78 ,  A01K2217/05 ,  A01K2227/105 ,  A61F2/14 ,  A61F2/16 ,  A61F9/007 ,  A61L27/227 ,  A61L27/34 ,  A61L2430/16 ,  C07K2319/20 ,  C07K2319/21 ,  G02C7/02 ,  C08L89/00

Abstract: The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes.

Abstract translation: 本发明提供由工程蛋白质制成的工程化蛋白质和生物医学产品。 生物医学产品包括可用于眼科用途的镜片。

公开(公告)号：WO03086305A8

公开(公告)日：2004-02-12

申请号：PCT/US0311061

申请日：2003-04-10

Applicant: UNIV CALIFORNIA ,  SCHWARTZ DANIEL M ,  DUNCAN KEITH ,  STEWART JAY

Inventor： SCHWARTZ DANIEL M ,  DUNCAN KEITH ,  STEWART JAY

IPC: A61K9/00 ,  A61K31/765 ,  A61K47/10 ,  A61L24/04 ,  A61K

CPC classification number: A61K9/0051 ,  A61K9/0048 ,  A61K47/10 ,  A61L24/046 ,  A61L2430/16 ,  C08L71/02

Abstract: The present invention relates to methods and pharmaceutical compositions involving the use of bioerodible (biodegradable) polymers to address fundamental needs in ocular surgery including sealants and sealing methods, barriers to cellular adhesion and proliferation, and mechanical barriers. In a particular embodiment, the present invention is also directed to the treatment of intraocular hypotony in an eye by limiting the flow of aqueous from the eye. In a preferred embodiment, application of a polymer, such as to the angle of the eye, limits the flow, thereby increasing the intraocular pressure.

Abstract translation: 本发明涉及涉及使用生物可降解（可生物降解的）聚合物来满足眼睛手术中的基本需要的方法和药物组合物，包括密封剂和密封方法，细胞粘附和增殖的障碍以及机械屏障。 在一个具体实施方案中，本发明还涉及通过限制水中从眼睛的流动来治疗眼内的眼内低通。 在优选的实施方案中，聚合物的应用（例如眼睛的角度）限制了流动，从而增加了眼内压。

公开(公告)号：WO2005107649A3

公开(公告)日：2006-11-30

申请号：PCT/US2005014939

申请日：2005-04-29

Applicant: CALHOUN VISION INC ,  GRUBBS ROBERT H ,  BRAIT AXEL ,  CHANG SHIAO H ,  NISHI OKIHIRO ,  SCHWARTZ DANIEL M

Inventor： GRUBBS ROBERT H ,  BRAIT AXEL ,  CHANG SHIAO H ,  NISHI OKIHIRO ,  SCHWARTZ DANIEL M

IPC: A61F2/16 ,  A61F2/30 ,  A61F9/00 ,  A61L31/06

CPC classification number: A61F2/1613 ,  A61F2/1629 ,  A61F2/1635 ,  A61F9/0017 ,  A61F2002/30583 ,  A61F2210/0085 ,  A61F2250/0012 ,  A61L31/06 ,  A61L2430/16 ,  C08L83/04

Abstract: When a natural lens (8) of the eye is removed through known processes such as phacoemulsification, an intraocular lens (12) is needed to restore the focusing power of the eye. The intraocular lens (12) is secured in place through the use of haptics which engage the wall of the capsular bag (14). Once the intraocular lens (12) is in place, the capsular bag (14) is filled with a composition (13) that is curable, providing an anchor for the intraocular lens (12). The composition (13) also helps in the accommodation process.

Abstract translation: 当通过诸如晶状体乳化的已知过程去除眼睛的天然晶状体（8）时，需要眼内透镜（12）来恢复眼睛的聚焦力。 通过使用与囊袋（14）的壁接合的触觉件将眼内透镜（12）固定就位。 一旦眼内透镜（12）就位，则囊袋（14）填充有可固化的组合物（13），为眼内透镜（12）提供锚固件。 组合物（13）还有助于调节过程。

公开(公告)号：WO2004098506A3

公开(公告)日：2004-11-18

申请号：PCT/US2004/013332

申请日：2004-04-30

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SCHWARTZ, Daniel, M. ,  DUNCAN, Keith, G. ,  BAILEY, Kathy, R. ,  KANE, John ,  ISHIDA, Brian, Y.

Inventor： SCHWARTZ, Daniel, M. ,  DUNCAN, Keith, G. ,  BAILEY, Kathy, R. ,  KANE, John ,  ISHIDA, Brian, Y.

IPC: A61K38/00

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

公开(公告)号：WO2004004757A1

公开(公告)日：2004-01-15

申请号：PCT/US2003/020672

申请日：2003-07-07

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE CALIFORNIA INSTITUTE OF TECHNOLOGY ,  SCHWARTZ, Daniel, M. ,  FRASER, Scott ,  GRUBBS, Robert, H. ,  GALLIVAN, Justin, P. ,  YU, C., J.

Inventor： SCHWARTZ, Daniel, M. ,  FRASER, Scott ,  GRUBBS, Robert, H. ,  GALLIVAN, Justin, P. ,  YU, C., J.

IPC: A61K38/43

CPC classification number: A61K49/0056 ,  A61K38/482 ,  A61K41/00 ,  A61K49/0017

Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.

Abstract translation: 本发明涉及改变眼中至少一个组织的至少一部分的物理和/或化学特性。 在一个具体的实施方案中，它涉及任何眼部疾病的治疗，尽管在具体实施方案中个体具有增厚的布鲁赫氏膜。 利用激活能量源来实现布鲁赫膜的受控扩散增强和/或降解，其能够改善脉络膜和视网膜之间的扩散传输。 向个体施用失活的扩散增强分子，其与膜相关联，然后将其精确暴露于活化能源如光或超声波。